New Clinical Study From Rational Therapeutics Doubles Response Rate in Patients With Advanced Lung Cancer; Personalized Treatment for Lung Cancer Comes of Age

LONG BEACH, Calif.--(BUSINESS WIRE)--Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD®) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics (http://www.rational-t.com) and the MemorialCare Todd Cancer Institute (Long Beach, CA) and published in the October issue of Anticancer Research.